Strategic Consulting and Advisory Services
Certara is the largest and most comprehensive provider of biosimulation (modeling and simulation), strategic pharmacometrics, and regulatory writing consulting services. Our multidisciplinary team works alongside clients to inform key drug development decisions and expedite the processes around achieving regulatory milestones.
Software Portfolio: 'End-to-end' Modeling
Certara biosimulation (model based drug development and informatics) software portfolio is the most wide-ranging in the industry. Certara technology is relied upon by over 1,500 biopharm companies and academic institutions for drug research and development.
Certara's Programmatic Consulting Approach Delivers Unquestionable Value to Sponsor Companies
Certara combines its industry renowned pharmacometric and regulatory consultants with our vast software portfolio to provide services that focus on specific outcomes, therapeutic areas, regulatory milestones, and specific populations.
Leading Edge Science: Resource Library
Check out the latest brochures, case studies, white papers, webinars, and more! Search by keywords and/or filter results.
D360 Licensed by Top 15 Global Pharmaceutical Company for Data Integration and Data Mining
July 12, 2011
D360 selected as enterprise solution for data integration, with data mining, analysis and visualization capabilities
ST. LOUIS, MO – July 12, 2011 – Certara™, a leading provider of software and services to improve productivity and decision-making from drug discovery through clinical development, today announced that a top 15 global pharmaceutical company has licensed D360 as its enterprise solution for scientific data integration and data mining, visualization, and analysis.
D360 is used by scientists to access multiple types of data, including chemical, biological, PK/PD data and more, regardless of database location and architecture. D360’s integrated analysis and visualization tools mean that scientists can quickly and easily get a view of their data, and perform analyses that accelerate scientific understanding, in just a few mouse clicks, without having to learn multiple applications. With D360, users can easily present and share complex research data and their findings in a format conducive to their research tasks, leading to streamlined project team collaboration and better informed decisions all through a self-supporting user community that requires little IT support. Additionally, the generation of data views, complete with analyses, can be automated for regular tasks, further streamlining scientists’ workflows.
“More and more pharma, biotech, and related research teams are now looking for improved data integration, data mining and analysis solutions to streamline their workflows and focus on science and innovation. D360 is the premier product for this essential need and demonstrates proven performance, scalability and cost effectiveness to be deployed at any size pharmaceutical or biotech organization to improve research effectiveness by allowing easy access to rational data-driven decision making.” said James Hayden, Senior Vice President of Sales and Marketing for Certara. “Additionally, very low ongoing maintenance overhead makes D360 the most cost effective solution on the market for any size life science organization.”
More information about D360’s data integration, data mining, visualization and analysis capabilities can be found here.
About Certara
Certara is dedicated to improving human health through a broad spectrum of products and services, from molecular discovery to clinical research. Formed in 2008, Certara unites Tripos (http://www.tripos.com) and Pharsight Corporation (http://www.pharsight.com). Tripos provides innovative scientific solutions enabling life science researchers to improve the efficiency of molecular discovery. Pharsight provides software and scientific services to improve productivity and decision-making in clinical drug development. Certara focuses on reducing the barriers between the phases of research to speed discoveries in chemistry, and enabling pharmaceutical and biotechnology companies to achieve significant and enduring improvements in the development and use of therapeutic products.
Back to News